Similar articles

• Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.

  Flynn DM, Hoffbrand AV, Politis D. Flynn DM, et al. Birth Defects Orig Artic Ser. 1982;18(7):347-53. Birth Defects Orig Artic Ser. 1982. PMID: 6819017 No abstract available.
• [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].

  Ferrara M, Galdo Capotorti M, Ponte G, Esposito L. Ferrara M, et al. Pediatria (Napoli). 1983 Oct-Dec;91(4):371-7. Pediatria (Napoli). 1983. PMID: 6545400 Italian. No abstract available.
• Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.

  Silvestroni E, Bianco I, Graziani B, Lerone M, Valente M, Congedo P, Ponzini D, Costantini S. Silvestroni E, et al. Acta Haematol. 1982;68(2):115-23. doi: 10.1159/000206962. Acta Haematol. 1982. PMID: 6812366
• Advances in the use of iron-chelating agents for the treatment of iron overload.

  Modell B. Modell B. Prog Hematol. 1979;11:267-312. Prog Hematol. 1979. PMID: 392593 Review. No abstract available.
• Measurement of iron status.

  Pippard MJ. Pippard MJ. Prog Clin Biol Res. 1989;309:85-92. Prog Clin Biol Res. 1989. PMID: 2675108 Review. No abstract available.